Loading
Ivonescimab / Pleural Mesotheliomas · Phase 2 Trial
ClinicalTrials.gov · August 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registered Phase 2 trial evaluating the bispecific antibody ivonescimab in patients with pleural mesothelioma that has progressed after prior immunotherapy and chemotherapy. No results are yet reported in this registry record; the trial is currently recruiting and the primary outcome (disease control rate at 12 weeks) has not been assessed.
Phase 2, Interventional, Single Group, Open label, Treatment purpose. Pleural Mesotheliomas; age from 18 Years. Intervention: Ivonescimab. n = 38. 21 sites: France.
This is a registered Phase 2 trial evaluating the bispecific antibody ivonescimab in patients with pleural mesothelioma that has progressed after prior immunotherapy and chemotherapy. No results are yet reported in this registry record; the trial is currently recruiting and the primary outcome (disease control rate at 12 weeks) has not been assessed.
No safety, tolerability, or secondary efficacy data provided in this record.
No clinical impact can yet be assessed, as this trial has not reported results. Clinicians should await completion and publication of outcome data before considering ivonescimab in this indication.
This is a registered Phase 2 trial with no reported results; it is recruiting and has not yet generated outcome data.
As stated by the source record.
Quoted from the source exactly as published.
No clinical impact can yet be assessed, as this trial has not reported results. Clinicians should await completion and publication of outcome data before considering ivonescimab in this indication.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06840834). This is a study registration, not published results. Lead sponsor: Intergroupe Francophone de Cancerologie Thoracique. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 38 participants (ESTIMATED). Conditions: Pleural Mesotheliomas. Interventions: DRUG: Ivonescimab. Primary outcome measures: To assess the therapeutic value of the bispecific antibody anti-VEGF / anti-PD-1 ivonescimab as 2nd/3rd line treatment in relapsing PM patients , 12 weeks after start of treatment.. Brief summary: Multicentre, open-label, single arm phase II study for patients with PM previously treated by immunotherapy and standard chemotherapy. 38 patients will be given second or third-line treatment with ivonescimab 20mg/kg every 3 weeks. An estimated 38 patients will be enrolled in approximately 20 centres. Patients will be treated for a maximum of 2 years, until disease progression, unacceptable toxicity, withdrawal of consent or another discontinuation criterion is met. The null hypothesis is disease control rate (DCR) at 12 weeks ≤ 30%. The alternative hypothesis is DCR ≥ 55% at 12 weeks.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.